摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Deoxy-D-glycero-D-gulo-heptitol | 5328-46-1

中文名称
——
中文别名
——
英文名称
1-Deoxy-D-glycero-D-gulo-heptitol
英文别名
heptane-1,2,3,4,5,6-hexol
1-Deoxy-D-glycero-D-gulo-heptitol化学式
CAS
5328-46-1
化学式
C7H16O6
mdl
——
分子量
196.2
InChiKey
CCLARULDIPFTCP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.7
  • 重原子数:
    13
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    121
  • 氢给体数:
    6
  • 氢受体数:
    6

SDS

SDS:1fe808cae80ed64332e22344243bbb25
查看

文献信息

  • [EN] 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS<br/>[FR] COMPOSÉS 3,5-DIAMINO -6-CHLORO-N-(N- (4-PHÉNYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE
    申请人:PARION SCIENCES INC
    公开号:WO2014099673A1
    公开(公告)日:2014-06-26
    The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.
    本发明涉及以下化合物的公式:或其药学上可接受的盐,用作通道阻滞剂,以及含有这些化合物的组合物,制备这些化合物的方法,以及在促进粘膜表面合和治疗包括囊性纤维化、慢性阻塞性肺病、哮喘、支气管扩张、急性和慢性支气管炎、肺气肿和肺炎等疾病的治疗方法。
  • CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY
    申请人:Parion Sciences, Inc.
    公开号:US20140171447A1
    公开(公告)日:2014-06-19
    This invention provides compounds of the formula I: and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.
    这项发明提供了式I的化合物及其药用盐,可用作通道阻滞剂,包含这些化合物的组合物,以及用于这些化合物的治疗方法和用途,以及制备这些化合物的方法。
  • ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    申请人:AbbVie Inc.
    公开号:US20170355769A1
    公开(公告)日:2017-12-14
    The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    这项发明涉及B7同源物3蛋白(B7-H3)抗体抗体药物结合物(ADCs),包括使用所述抗体和ADCs的组合物和方法。
  • [EN] ANTI-EGFR ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ANTI-EGFR
    申请人:ABBVIE INC
    公开号:WO2017214282A1
    公开(公告)日:2017-12-14
    The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. Formula (IIa), (IIb), (IIc)
    本发明涉及抑制Bcl-xL的抗表皮生长因子受体(EGFR)抗体药物偶联物(ADCs),包括所述ADCs的组成和方法。公式(IIa),(IIb),(IIc)
  • 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS
    申请人:Parion Sciences, Inc.
    公开号:US20140170244A1
    公开(公告)日:2014-06-19
    The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.
    本发明涉及以下式的化合物: 或其药用可接受的盐,用作通道阻滞剂,以及含有相同化合物的组合物,制备相同化合物的方法,以及在促进粘膜表面合和治疗包括囊性纤维化、慢性阻塞性肺病、哮喘、支气管扩张、急性和慢性支气管炎、肺气肿和肺炎等疾病的治疗方法。
查看更多